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Abstract
Aims To evaluate the timing and spectral-domain optical coherence tomography (SD-OCT) features of diabetic macular 
oedema (DME) recurrence according to baseline OCT patterns in patients treated with dexamethasone implant (DEX-I).
Methods This is a retrospective observational study (72 eyes/65 patients). Best-corrected visual acuity, timing of DME 
recurrence, and SD-OCT pattern [intraretinal cysts (IRC), IRC plus subretinal fluid (mixed), external limiting membrane 
(ELM), ellipsoid (IS/OS) layer integrity] were assessed at baseline and monthly until first DME recurrence.
Results Forty-two (58.3%) and 30 (41.6%) DME eyes had an IRC and mixed DME pattern at baseline, respectively. Twenty-
four out of thirty mixed eyes (80%) relapsed without subretinal fluid. At baseline, mixed eyes showed similar changes in 
ELM and IS/OS (60 and 76.6% of eyes, respectively) versus IRC eyes (42.8 and 80.9% of eyes). After DME recurrence, more 
mixed eyes at baseline showed ELM and IS/OS changes (63.3 and 86.6%) than IRC eyes (50 and 76.2%). 33.3% of mixed 
eyes had DME recurrence at ≥ 6 months from first DEX-I implant versus 19% of IRC eyes.
Conclusions Mixed DME eyes were treated with DEX-I relapse later and more frequently without subretinal fluid than IRC 
eyes. SD-OCT characteristics of different DME patterns at baseline can predict morphological features and timing of DME 
recurrence.
Keywords Diabetic macular oedema · Dexamethasone implant (DEX-I) · Intravitreal treatment · Baseline characteristics · 
Recurrence · Spectral-domain optical coherence tomography
Introduction
Diabetic macular oedema (DME), a macular thickening 
secondary to diabetic retinopathy (DR), results from a 
blood–retinal barrier defect that leads to vascular leakage 
and fluid accumulation [1]. In patients with diabetes, DME 
is a leading cause of visual impairment and loss [2] and has 
been reported in almost 30% of patients with a duration of 
disease > 20 years [3].
DME has been related to the expression of several inflam-
matory factors, including vascular endothelial growth factor 
(VEGF), intercellular adhesion molecule-1 (ICAM-1), inter-
leukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), 
and leukostasis [4, 5]. Moreover, the expression of these 
factors has been related to both vascular permeability of the 
retina along with the severity of disease, thus confirming 
their important pathogenetic role [4]. While achieving con-
trol of glycemia is essential to limit the progression of DME, 
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several treatment options for patients with DME are also in 
widespread use [2, 6]. Indeed, in the past decade, advances 
in the understanding of the pathogenesis of DME have led 
to the development of new therapies with anti-inflamma-
tory action, especially steroids and VEGF inhibitors, which 
have resulted in several novel therapeutic applications [2, 7]. 
While intravitreal anti-VEGF agents have been shown to be 
effective in improving best-corrected visual acuity (BCVA) 
and decreasing central retinal thickness (CRT), it has been 
suggested that they should be used with caution due to pos-
sible systemic adverse events [2]. Moreover, they are not 
appropriate for all patients, and not all patients respond to 
anti-VEGF treatment; compliance to therapy also remains 
suboptimal due to the numerous injections required [8, 9].
In addition to anti-VEGF agents, in diabetic animal mod-
els, intravitreal corticosteroids have been shown to block 
the production of several inflammatory mediators, such as 
VEGF and ICAM-1, and inhibit leukostasis [10, 11]. In a 
clinical context, dexamethasone has been shown to have the 
highest relative efficacy among all corticosteroids that are 
routinely used to treat DME [6].
Dexamethasone intravitreal implant (DEX-I) is a matrix 
based on micronized dexamethasone embedded in a bio-
degradable copolymer of polylactic-co-glycolic acid that 
slowly releases the steroid into the vitreous over a period 
of months [12, 13]. DEX-I has been studied extensively in 
patients with DME. Based on the MEAD study, the Food 
and Drug Administration (FDA) and European Medicines 
Agency (EMA) approved DEX-I for the treatment of DME 
[14].
Several subsequent studies further demonstrated that 
DEX-I could improve BCVA and CRT in patients with DME 
and thus represents a viable treatment option [15, 16]. Simi-
lar results were obtained from the analysis of real-life data 
[17, 18]. A meta-analysis of four randomized clinical trials 
involving 521 eyes with DME reported that DEX-I is asso-
ciated with improvements in BCVA that are non-inferior 
to anti-VEGF therapy, with superior anatomic outcomes at 
6 months [6]. Moreover, compared to anti-VEGF agents, 
DEX-I requires fewer injections with no significant differ-
ences in the rates of adverse events, although there was some 
concern over raised intraocular pressure and cataract com-
pared to anti-VEGF therapy. Given these favourable charac-
teristics, DEX-I may be considered as first-choice therapy in 
selected cases, such as for pseudophakic eyes, failure of an 
anti-VEGF-agent, or in patients who are unwilling or unable 
to undergo frequent intravitreal injections [6].
To date, there is still limited evidence on the impact that 
individual characteristics of DME may have on the recur-
rence of DME following the implant of DEX-I. Some evi-
dence has been presented that the DME morphologic sub-
types, as defined by optical coherence tomography (OCT), 
may be associated with greater reductions in CRT in patients 
with DME. In particular, the serous retinal detachment 
(SRD) subtype has been associated with a greater reduction 
in the CRT than the diffuse retinal thickening (DRT) sub-
type [19], and in another study, the cystoid macular oedema 
(CME) and SRD subtypes showed greater reduction in CRT 
than the DRT subtype [20]. To shed further light on this 
aspect, we evaluated the spectral-domain (SD)-OCT mor-
phological features of DME recurrence according to baseline 
OCT patterns in patients treated with DEX-I.
Materials and methods
Study design and patient population
This was a retrospective observational study. Informed con-
sent was obtained from all subjects. All research procedures 
described in this study adhered to the tenets of the 1964 
Declaration of Helsinki and its later amendments.
Clinical charts were retrieved from the four participating 
centres, and the pooled data were analysed. We included 
patients with a diagnosis of DME who had been treated with 
DEX-I during the period from 1 January 2017 to 30 June 
2018 and followed at least until the first recurrence of DME 
at four referral centres (University of Torino, IRCCS-Fon-
dazione Bietti in Rome, University of Siena, and Rothschild 
Foundation in Paris).
All patients had data relating to BCVA and SD-OCT fea-
tures available at baseline and at each follow-up examina-
tion. BCVA was measured using the Early Treatment Dia-
betic Retinopathy Study (ETDRS) charts and reported as 
LogMar. Follow-up examinations included maximal answer 
(defined as macula dry or with the minimum amount of 
intra- or subretinal fluid) and information on DME recur-
rence (mean recurrence timing, characteristics of DME on 
SD-OCT). Baseline data also included the following: demo-
graphic data, diabetes duration, per cent glycated haemoglo-
bin  (HbA1c) level, and information on previous intravitreal 
treatment. Exclusion criteria were: macular oedema second-
ary to causes other than diabetes; previous treatment with 
intraocular corticosteroids; previous anti-VEGF intravitreal 
injections within the 6 months before treatment with the 
DEX implant; previous macular laser; and previous pars 
plana vitrectomy.
SD-OCT images were acquired with a Spectralis 
HRA + OCT instrument (Heidelberg Engineering, Heidel-
berg, Germany, version 6.4.7.0). The scanning protocol 
included a high-resolution 20° × 20° volume scan centred in 
the central macula. CRT was measured using the retina map 
pattern and the provided ETDRS grid in the central millime-
tre. Each section was obtained using ART (automatic real-
time) eye tracking, and 16 scans were averaged to improve 
the signal-to-noise ratio. The following SD-OCT features 
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were considered: CRT, DME pattern classified according to 
the presence of intraretinal cysts (IRC) or IRC plus subreti-
nal fluid (mixed) pattern, the integrity of the external limit-
ing membrane (ELM), and the ellipsoid junction (IS/OS).
The BCVA and SD-OCT characteristics were evaluated 
by two expert observers (CME and MP) at baseline and then 
monthly after DEX-I treatment until the first recurrence of 
DME. Patients were retreated according to a pro re nata 
(PRN) regimen if there was a recurrence of DME, defined 
as the presence of intra- or subretinal fluid on SD-OCT, also 
in the absence of visual impairment.
Statistical analysis
The normal data distribution was tested using the one-sam-
ple Kolmogorov–Smirnov test. All continuous variables 
were expressed as mean ± standard deviation, while cat-
egorical variables as frequency and percentage. T test and 
Mann–Whitney test were performed as appropriate. Contin-
gency tables (chi-square test) were used to investigate the 
relationship between pre- and post-recurrence DME pat-
tern and between baseline DME pattern and pre- and post-
recurrence morphological parameters (ELM and IS/OS). A 
one-way repeated measures analysis of variance (ANOVA) 
for each group was conducted to evaluate the null hypoth-
esis that there is no change in functional and morphologi-
cal parameter values when measured at baseline, maximal 
answer, and after recurrence in study groups. Post hoc tests 
were performed using the Bonferroni correction. Statistical 
evaluation was performed using SPSS (IBM SPSS Statistic 
25). A p value < 0.05 was considered statistically significant.
Results
Baseline demographic characteristics
Considering pooled data from the four centres, baseline 
information and follow-up data were available on a total of 
72 eyes from 65 patients with DME and receiving a DEX-I. 
The cohort included 39 males (60%) and 26 females (40%), 
with a mean age of 57.2 ± 8.2 years, mean duration of type 
2 diabetes of 17.2 ± 8.8 years, and mean per cent  HbA1C 
at baseline of 8.2 ± 1.8 (66.0 ± 17.3 mmol/mol). Forty-three 
of the 72 eyes (59.7%) were phakic, and 29 (40.3%) were 
pseudophakic. Thirty-nine of the 72 eyes (54.2%) were naïve 
to treatment, and 33 of 72 eyes (45.8%) were switched from 
previous anti-VEGF treatment (Table 1).
SD‑OCT features
Forty-two (58.3%) and 30 (41.6%) eyes presented with 
an IRC and mixed DME pattern at baseline, respectively. 
Maximal answer (macula dry or with the minimum amount 
of intra- or subretinal fluid) timing was 1.83 ± 0.80 months 
for all patients, 1.83 ± 0.82 months for IRC group, and 
1.83 ± 0.79 for the mixed group. Twenty-four of 30 mixed 
eyes (80%) treated with DEX-I relapsed without subreti-
nal fluid (Table 2). A significant relationship was found 
between basal and post-recurrence DME pattern, X2 (1, 
n = 72) = 6.19, p = 0.013. A Mann–Whitney test showed 
that no differences were present in mean recurrence 
timing of baseline IRC and mixed groups (IRC group 
5.74 ± 1.98  months; mixed group 6.27 ± 2.69  months, 
p = 0.168). However, a higher percentage of mixed eyes 
(33.3%) had a recurrence of DME after 6 months or longer 
after the first DEX-I implant in comparison with IRC eyes 
(19%) (Table 2). Figure 1 shows the SD-OCT features of a 
representative patient with mixed pattern DME before, 2 
months after, and at the time of recurrence 7 months after 
treatment with DEX-I.
At baseline, mixed eyes showed similar changes in ELM 
and IS/OS (60 and 76.6% of eyes, respectively) compared 
with IRC eyes (42.8 and 80.9% of eyes, respectively). After 
Table 1  Demographic and baseline characteristics of patients
n number, SD standard deviation, HbA1c glycated haemoglobin




Age, mean ± SD (years) 57.2 ± 8.2
Duration of diabetes (years) mean ± SD 17.2 ± 8.8 
(range 
5–45)
HbA1c % (mean ± SD) 8.2 ± 1.8a
Phakic/pseudophakic (n eyes) 43/29
Naïve/switched (n eyes) 39/33
Table 2  Baseline DME pattern versus post-recurrence DME pattern 
and timing of recurrence




Post-recurrence DME pattern, eyes (%)
 IRC 41/42 (97.6) 24/30 (80.0) 0.013
 Mixed 1/42 (2.4) 6/30 (20.0)
Mean recurrence timing, 
months ± SD
5.74 ± 1.98 6.27 ± 2.69 0.625
 > 6 months, eyes (%) 8/42 (19.0) 10/30 (33.3) 0.168
 ≤ 6 months, eyes (%) 34/42 (81.0) 20/30 (66.6)
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a recurrence of DME, baseline mixed eyes showed greater 
changes in ELM and IS/OS (63.3% and 86.6% of eyes, 
respectively) compared with IRC eyes (50 and 76.2% of 
eyes, respectively) (Table 3).
By T test, a significant difference was found between 
basal CRT of the IRC and mixed groups at baseline (IRC 
516 ± 136 μm; mixed 600 ± 116 μm; p = 0.008). Moreover, 
significant differences between groups were found in CRT 
at post-recurrence (IRC at baseline 462 ± 131 μm; mixed at 
baseline group 614 ± 150 μm; p = 0.006).
In both the IRC and mixed groups, ANOVA indicated a 
significant effect of time on CRT (p < 0.01). Post hoc tests 
indicated that pairwise differences in the IRC group were 
significant between baseline (516 ± 136 μm) and maximal 
answer (307 ± 76 µm) time (p = 0.009) and between maximal 
answer and post-recurrence (460 ± 135 μm) time (p < 0.01). 
In the mixed group, there was a significant decrease in 
CRT values between baseline (600 ± 116 µm) and maximal 
answer (336 ± 93 μm) time, as well as an increase between 
maximal answer and post-recurrence (499 ± 145 μm) time. 
The maximal answer for both groups was at month 2.
At baseline, treatment-naïve eyes showed fewer IS/OS 
changes than switched eyes in both subgroups of DME pat-
terns (66.7% vs. 91.7% in IRC and 60% vs. 85% in the mixed 
group) (Table 4). After a recurrence of DME, a similar trend 
was observed: Naïve eyes showed fewer IS/OS changes than 
switched eyes in both subgroups of DME patterns (61.1% vs. 
87.5% in IRC and 70% vs. 95% in the mixed group).
At baseline and after recurrence of DME, a non-statis-
tically significant difference in terms of ELM changes was 
Fig. 1  Left: Fluorescein angiography a of a patient with diabetic 
macular oedema before the treatment with dexamethasone intra-
vitreal implants (DEX-I). Top right: Spectralis thickness map (b) 
and B-scan c of the same patient before the treatment with DEX-I, 
showing intraretinal cysts and subretinal fluid (mixed pattern). Mid-
dle right: Spectralis thickness map (d) and B-scan e of the same 
patient 2  months after the treatment with DEX-I showing a reduc-
tion in the macular thickness and no intra- or subretinal fluid. Bottom 
right: Spectralis thickness map (f) and B-scan g of the same patient 
7 months after the treatment with DEX-I showing new diabetic macu-
lar oedema with intraretinal cysts without subretinal fluid
Table 3  Spectral-domain 
optical coherence tomography 
(SD-OCT) characteristics by 
group
CRT central retinal thickness, ELM external limiting membrane, IRC intraretinal cysts, IS/OS ellipsoid 
junction, SD standard deviation
SD-OCT characteristics IRC Mixed p
Baseline IS/OS changes, eyes (%) 34/42 (80.95) 23/30 (76.67) 0.659
Baseline ELM changes, eyes (%) 18/42 (42.86) 18/30 (60.00) 0.151
Post-recurrence IS/OS changes, eyes (%) 32/42 (76.20) 26/30 (86.70) 0.268
Post-recurrence ELM changes, eyes (%) 21/42 (50.00) 19/30 (63.30) 0.262
Mean baseline CRT (μm ± SD) 516 ± 136 600 ± 116 0.008
Mean post-recurrence CRT (μm ± SD) 462 ± 131 614 ± 150 0.006
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found between treatment-naïve and switched eyes in both 
subgroups of DME patterns (baseline: 50% vs. 37.5% in 
IRC and 70% vs. 55% in the mixed group; after recurrence: 
50% vs. 50% in IRC and 70% vs. 60% in the mixed group) 
(Table 4).
BCVA characteristics
A T test showed no differences between baseline BCVA 
(IRC 0.394 ± 0.287 LogMar; mixed 0.491 ± 0.334 LogMar) 
in the IRC and mixed groups (p = 0.195) and no differences 
between groups for post-recurrence BCVA (IRC at baseline 
0.437 ± 0.296 LogMar; mixed at baseline 0.290 ± 0.191 Log-
Mar; p = 0.202). In both the IRC and mixed groups, ANOVA 
indicated a significant time effect (p < 0.01) on BCVA. Post 
hoc tests indicated that pairwise differences in the IRC group 
were significant between baseline (0.394 ± 0.28 LogMar) 
and maximal answer (0.301 ± 0.21 LogMar) time (p = 0.009) 
and between maximal answer and post-recurrence time 
(0.377 ± 0.21 LogMar; p < 0.01). In the mixed group, a sig-
nificant difference between maximal answer (0.420 ± 0.36 
LogMar) and post-recurrence time (0.488 ± 0.037 LogMar; 
p = 0.015) was found.
Of note, no relevant safety issues were encountered dur-
ing follow-up in this patient cohort, confirming the previ-
ously reported favourable safety profile with DEX-I.
Discussion
Overall, the present analysis found that mixed DME eyes 
treated with DEX-I relapsed with only intraretinal fluid, 
without subretinal fluid, and at a later time compared to IRC 
eyes. Thus, the present data would seem to indicate that the 
SD-OCT characteristics that define different DME patterns 
at baseline may be useful in predicting the morphological 
features and timing of recurrence of DME. These findings 
further confirm the utility of SD-OCT in identifying param-
eters that can be predictive of a better and longer response 
to DEX-I.
The possibility of identifying morphological biomarkers 
in DME that can predict a better response to DEX-I is of 
substantial clinical interest. In this regard, OCT is a fast 
and noninvasive examination routinely used in daily clini-
cal practice, and its application in this setting has important 
implications for the management of patients with diabetic 
maculopathy. Moreover, the present analysis suggests that 
patients with an IRC pattern may relapse more frequently 
and sooner. This provides the clinician with additional infor-
mation that can help to individualize treatment with DEX-I 
and help in selecting patients who may be the most appro-
priate candidates for this therapy. For example, in patients 
who are predicted to relapse earlier, more frequent follow-up 
may be warranted in order to modulate treatment accord-
ingly or to allow for earlier switching to another treatment, 
as with other therapies such as anti-VEGF [21]. One addi-
tional advantage of better prediction of relapse and time to 
relapse is that early implantation of DEX-I has been associ-
ated with better visual outcomes. Indeed, significantly more 
eyes showing a robust early response demonstrated ≥ 10-let-
ter long-term gain in BCVA compared to eyes with poor 
early response [22].
Considering specific OCT features, in the present analy-
sis, we found that mixed eyes treated with DEX-I relapsed 
later than IRC eyes. We could speculate that a higher per-
centage of mixed eyes had a recurrence of DME later than 
IRC eyes because the presence of SRF in mixed eyes could 
denote an inflammatory nature of macular oedema that could 
be better opposed by the action of DEX-I. These results are 
consistent with the study by Zur et al., which found that 
eyes with DME and subretinal fluid (SRF), no hyperreflec-
tive foci (HRF), and a continuous IS-OS layer responded 
better to DEX-I than those without these features [23]. The 
recurrence of DME without SRF observed in 80% of mixed 
eyes treated with DEX-I could also confirm the inflamma-
tory nature of SRF, which do not reappear in the recurrence 
of DME after DEX-I treatment. In support of this hypoth-
esis, previous studies have reported that higher concentra-
tions of inflammatory cytokines in the vitreous and aqueous 
humour are present in eyes with SRF, thus suggesting the 
presence of a significant inflammatory component [4, 24]. 
Moreover, in our study, eyes with SRF at baseline showed 
greater changes in ELM than eyes without SRF (60% vs. 
42.8%, respectively). This finding is of interest, consider-
ing that previous authors have reported that the integrity 
of the ELM seems to be a key factor in preventing fluid 
Table 4  SD-OCT changes 
of ELM and IS/OS layers by 
subgroup of patients (naïve, 
switched)
ELM external limiting membrane, IRC intraretinal cysts, IS/OS ellipsoid junction
SD-OCT changes, eyes (%) IRC Mixed
Naïve Switched p Naïve Switched p
Baseline IS/OS 12/18 (66.7) 22/24 (91.7) 0.041 6/10 (60.0) 17/20 (85.0) 0.127
Baseline ELM 9/18 (50) 9/24 (37.5) 0.418 7/10 (70.0) 11/20 (55.0) 0.429
Post-recurrence IS/OS 11/18 (61.1) 21/24 (87.5) 0.047 7/10 (70.0) 19/20 (95.0) 0.058
Post-recurrence ELM 9/18 (50.0) 12/24 (50.0) 1 7/10 (70.0) 12/20 (60.0) 0.592
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from passing from the outer retina into the subretinal space 
[25]. The post-recurrence OCT features of eyes with DME 
showed that eyes with SRF had more changes in both the 
IS/OS and ELM layers compared to eyes without SRF (86.7 
and 63.3%, respectively, for mixed eyes vs. 76.2 and 50% for 
IRC eyes). In this regard, we speculate that SRF at baseline 
could be associated with damage to the IS/OS in the long 
term. Moreover, since there are no changes at the level of 
the ELM between the baseline and the post-recurrence the 
low rate of recurrence of SRD might depend on the timing of 
retreatment that was performed as soon as intraretinal fluid 
appeared and before the development of subretinal fluid.
DEX-I is significantly associated with improved anatomi-
cal outcomes (although not necessarily BCVA) and has been 
recommended as first-choice therapy for pseudophakic eyes, 
those resistant to anti-VEGF agents, or for patients who are 
reluctant to receive frequent intravitreal injections [6]. In 
fact, several studies have reported that DEX-I is effective 
for the treatment of DME, even in refractory cases that have 
failed to respond to other therapies, substantiating its utility 
in these patients [19, 26].
We also examined the difference between eyes naïve to 
treatment and eyes switched from previous intravitreal anti-
VEGF in all cases. Interestingly, at baseline and at the post-
recurrence time, treatment-naïve eyes showed fewer IS/OS 
changes than switched eyes in both groups, with a significant 
difference in IRC eyes and a statistical trend in mixed eyes. 
Zur et al. [23] reported that eyes with a continuous IS/OS 
layer respond better to DEX-I, and thus we can speculate that 
eyes naïve to treatment have better preservation of the IS/
OS layer compared to switched eyes and thus have a better 
response to DEX-I. Notwithstanding, the efficacy of DEX-I 
in DME has been confirmed in both naïve and refractory 
patients [26, 27], as well as in real-world analyses [28].
Studies on prognostic indicators with the use of DEX-I 
in patients with DME have reported that visual and ana-
tomical outcomes of treatment with DEX-I may be predicted 
by baseline visual acuity and intraretinal fluid morphology 
[29]. Recent data have further indicated that elevated MCP-1 
aqueous humour levels and DRT pattern at baseline are bio-
markers that predict future favourable anatomic response to 
DEX-I [30]. Thus, the present data add to the growing list 
of clinical markers that can help predict response to DEX-
I. This is important as DEX-I is recommended in current 
guidelines as first- or second-line therapy in subjects with 
DME [31, 32] and represents a valid therapeutic alternative 
to other medical treatments, as also demonstrated in direct 
comparisons with anti-VEGF agents at 12 and 24 months 
[33, 34].
The present study has some limitations, such as its retro-
spective design and relatively low number of patients, and 
larger studies with additional ophthalmologic parameters are 
warranted to confirm our findings. Moreover, we decided 
not to include in the current analysis some anatomical prog-
nostic parameters, such as hyperreflective foci and disor-
ganization of retinal inner layers (DRIL), because of their 
lower application on clinical routine examination. How-
ever, it could be interesting in a further study to evaluate the 
association between these parameters, already described as 
important clinical and prognostic factors for DME [35, 36], 
and the pattern of DME.
We can nonetheless confirm the utility of SD-OCT in 
identifying parameters that can be predictive of better and 
longer response to DEX-I, thus reinforcing the need to fur-
ther study combinations of SD-OCT and metabolic biomark-
ers. One such candidate for study is intracellular adhesion 
molecule 1, which has been shown to correlate with subreti-
nal fluid height in DME [37].
In conclusion, most mixed DME eyes treated with DEX-I 
relapse without subretinal fluid and at a later time than IRC 
eyes. The SD-OCT characteristics of different DME patterns 
at baseline can help to predict the morphological features 
and timing of DME recurrence.
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